Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

BIIB

Biogen Inc

Nov 07 • 04:00PM ET

155.51

-1.23 -0.78 %

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: VRTX GILD REGN AMGN MRK PFE BMY LLY JNJ NBIX

| Held by: VTI VOO QQQ VO IVV SPY VTV RSP XLV IBB

Index	NDX, S&P 500	P/E	14.18	EPS (ttm)	10.97	Insider Own	0.19%	Shs Outstand	146.70M	Perf Week	0.80%
Market Cap	22.81B	Forward P/E	10.22	EPS next Y	15.22	Insider Trans	-2.29%	Shs Float	146.43M	Perf Month	3.94%
Enterprise Value	25.44B	PEG	-	EPS next Q	1.87	Inst Own	93.01%	Short Float	3.55%	Perf Quarter	21.49%
Income	1.61B	P/S	2.35	EPS this Y	-8.76%	Inst Trans	0.61%	Short Ratio	3.17	Perf Half Y	31.60%
Sales	9.69B	P/B	1.25	EPS next Y	1.25%	ROA	5.59%	Short Interest	5.19M	Perf YTD	1.69%
Book/sh	124.11	P/C	5.76	EPS next 5Y	-1.44%	ROE	9.31%	52W High	176.95 -12.12%	Perf Year	-12.11%
Cash/sh	27.00	P/FCF	9.90	EPS past 3/5Y	2.46% -18.66%	ROIC	6.49%	52W Low	110.04 41.33%	Perf 3Y	-44.47%
Dividend Est.	-	EV/EBITDA	7.85	Sales past 3/5Y	-3.78% -6.13%	Gross Margin	65.99%	Volatility	3.14% 3.20%	Perf 5Y	-36.65%
Dividend TTM	-	EV/Sales	2.63	EPS Y/Y TTM	-1.03%	Oper. Margin	25.17%	ATR (14)	4.87	Perf 10Y	-42.51%
Dividend Ex-Date	-	Quick Ratio	2.04	Sales Y/Y TTM	5.00%	Profit Margin	16.60%	RSI (14)	60.95	Recom	2.16
Dividend Gr. 3/5Y	- -	Current Ratio	2.72	EPS Q/Q	19.26%	SMA20	4.47%	Beta	0.14	Target Price	176.44
Payout	0.00%	Debt/Eq	0.36	Sales Q/Q	3.33%	SMA50	6.47%	Rel Volume	0.87	Prev Close	156.74
Employees	7605	LT Debt/Eq	0.36	Earnings	Oct 30 BMO	SMA200	14.76%	Avg Volume	1.64M	Price	155.51
IPO	Sep 17, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	23.89% 8.32%	Trades		Volume	1,422,969	Change	-0.78%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-06-25	Upgrade	Stifel	Hold → Buy	$202
Sep-25-25	Initiated	Jefferies	Buy	$190
Jul-21-25	Resumed	Truist	Hold	$142
Apr-28-25	Downgrade	HSBC Securities	Buy → Hold	$118
Apr-04-25	Downgrade	Argus	Buy → Hold
Feb-11-25	Initiated	Bernstein	Mkt Perform	$160
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164
Dec-16-24	Downgrade	Stifel	Buy → Hold	$175
Dec-10-24	Resumed	BofA Securities	Neutral	$178
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$250 → $180
Nov-18-24	Downgrade	Needham	Buy → Hold
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-14-24	Initiated	Citigroup	Neutral	$190
Oct-31-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$285 → $204
Oct-10-24	Resumed	Raymond James	Mkt Perform
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240
Jan-24-24	Downgrade	UBS	Buy → Neutral	$311 → $276
Dec-20-23	Resumed	Cantor Fitzgerald	Overweight	$311

Show Previous Ratings

Nov-07-25 01:23PM	DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug (Zacks)
Nov-06-25 09:45AM	Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls (The Fly)
09:02AM	Here Are Thursdays Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More (24/7 Wall St.)
07:58AM	Stifel lifts Biogen to Buy, sees potential Alzheimers narrative shift (Investing.com)
12:38AM	5 Insightful Analyst Questions From Biogen's Q3 Earnings Call (StockStory)
04:49PM	Loading…
Nov-05-25 04:49PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
01:00AM	Braveheart secures $185M to advance challenger to Bristol Myers heart drug (BioPharma Dive)
Nov-03-25 07:30AM	Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
Oct-31-25 05:00PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
02:28PM	Analyst Report: Biogen Inc. (Morningstar Research)
10:15AM	BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands (StockStory)
Oct-30-25 04:27PM	Biogen Inc (BIIB) Q3 2025 Earnings Call Highlights: Strong Product Launch Growth and Strategic ... (GuruFocus.com)
04:07PM	Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem (Investor's Business Daily)
02:02PM	BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View (Zacks)
01:14PM	Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook (Zacks)
01:13PM	Loading…
01:13PM	Earnings roundup: Alnylams down day, Neurocrines head scratch and Biogens low quality win (BioPharma Dive)
09:53AM	Stock Market Today: Dow Falls After Trump-Xi Talks; Meta Plunges On Cost Worries (Live Coverage) (Investor's Business Daily)
09:30AM	Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:46AM	Biogen (NASDAQ:BIIB) Beats Q3 Sales Expectations (StockStory)
07:40AM	Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise (The Wall Street Journal)
07:15AM	Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates (Zacks)
06:57AM	Biogen shares slide as guidance cut overshadows Q3 earnings beat (Investing.com)
Oct-28-25 11:09PM	Biogen (BIIB) Reports Earnings Tomorrow: What To Expect (StockStory)
Oct-27-25 12:30PM	Analyst Report: Biogen Inc. (Morningstar Research)
10:00AM	Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for (Zacks)
07:46AM	Biogen acquires global rights to Vanqua C5aR1 antagonist (Pharmaceutical Business Review)
Oct-26-25 07:30PM	Health Canada Grants Authorization for "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease (GlobeNewswire)
Oct-24-25 10:58AM	Biogen licenses a possible immune drug from OrbiMed-backed biotech (BioPharma Dive)
10:33AM	Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key (Zacks)
07:30AM	Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio (GlobeNewswire)
10:00AM	Loading…
Oct-23-25 10:00AM	Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-22-25 07:30AM	Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 (GlobeNewswire)
Oct-16-25 12:05AM	3 Reasons BIIB is Risky and 1 Stock to Buy Instead (StockStory)
Oct-14-25 08:23AM	FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months (Zacks)
12:35AM	1 Healthcare Stock to Research Further and 2 We Find Risky (StockStory)
Oct-13-25 07:30PM	LEQEMBI IQLIK(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" (PR Newswire)
Oct-10-25 11:55AM	Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines? (Zacks)
04:36AM	What to Expect From Biogens Q3 2025 Earnings Report (Barchart)
Oct-09-25 04:30PM	Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome (Business Wire)
04:30PM	Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome (GlobeNewswire)
Oct-08-25 10:56AM	Can BMYs Neuroscience Portfolio Help to Diversify Its Business? (Zacks)
Oct-06-25 04:30PM	Eisai and Biogen Announce U.S. Availability of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease (PR Newswire)
Oct-02-25 12:42AM	3 Low-Volatility Stocks That Concern Us (StockStory)
Oct-01-25 08:16PM	Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT (Insider Monkey) +10.09%
07:04PM	Chart Master: A breakout could signal more upside for beaten-down pharma stocks (CNBC TV)
04:55PM	Drug Stock Rally Helps Push Dow and S&P 500 to Records (The Wall Street Journal)
02:48PM	Pharma stocks are powering the Nasdaq Composite and S&P 500 higher in afternoon trading (MarketWatch)
Sep-30-25 07:08PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
06:49AM	NMPA approves Eisai and Biogen for Leqembi IV maintenance dosing (Pharmaceutical Technology)
Sep-28-25 07:30PM	"LEQEMBI" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China (GlobeNewswire)
04:24PM	Biogen Inc. (BIIB): A Bull Case Theory (Insider Monkey)
Sep-27-25 12:59AM	Biogen (BIIB) Expands Neurology Pipeline With Alcyone Buyout, Stock Seen Undervalued (Insider Monkey)
Sep-26-25 10:32AM	LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy (Zacks)
08:24AM	The Baltics: a region punching above its weight on the global life sciences stage (Medical Device Network)
Sep-25-25 09:38AM	Oracle initiated, Ulta Beauty upgraded: Wall Street's top analyst calls (The Fly)
Sep-24-25 12:49PM	Biogens high-dose Spinraza turned down by FDA due to CMC troubles (Pharmaceutical Technology)
12:41PM	BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL (Zacks)
07:30AM	LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia (GlobeNewswire)
Sep-23-25 04:41PM	US FDA declines to approve higher dose of Biogen's genetic disorder drug (Reuters)
04:30PM	Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen (GlobeNewswire)
02:15PM	IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal (Zacks)
Sep-19-25 04:44AM	Biogen to acquire Alcyone Therapeutics for $85m (Pharmaceutical Business Review)
Sep-18-25 09:17AM	Biogen Gets EU Nod for First Postpartum Depression Drug (Zacks)
07:40AM	Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates (GlobeNewswire)
07:30AM	Biogens Zurzuvae approved as first postpartum depression drug in Europe (Pharmaceutical Technology)
07:07AM	Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs (BioPharma Dive)
Sep-17-25 04:30PM	Biogen Receives European Commission Approval for ZURZUVAE (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe (GlobeNewswire)
Sep-16-25 11:31PM	Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way (StockStory)
02:58PM	Canaccord Genuity Reiterates a Buy on Biogen (BIIB) (Insider Monkey)
Sep-15-25 09:03AM	H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects (Insider Monkey)
Sep-12-25 01:56PM	Is Biogen Stock Underperforming the Nasdaq? (Barchart)
Sep-11-25 07:00AM	GE HealthCare inks Icometrix buyout to acquire brain MRI software (MedTech Dive)
Sep-09-25 04:00AM	Can new Alzheimers tests help clear the way for the next generation of therapies? (Pharma Voice)
Sep-04-25 02:36PM	Biogen (BIIB) Stock Trades Down, Here Is Why (StockStory)
09:17AM	Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth? (Zacks)
Sep-03-25 10:47AM	IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride (Zacks)
Sep-02-25 09:05PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research) +5.60%
07:30PM	Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status (GlobeNewswire)
03:35PM	Biogen (BIIB) Stock Is Up, What You Need To Know (StockStory)
10:23AM	Stock Market Today: Nasdaq, S&P 500 down over 1% after holiday weekend (TheStreet)
10:01AM	Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales (Zacks)
09:51AM	Stock Market Today: Dow Dives 500 Points On Trump Tariff News; Nvidia, Palantir Sell Off (Live Coverage) (Investor's Business Daily)
09:48AM	These Stocks Are Moving the Most Today: Nvidia, PepsiCo, NIO, Constellation Brands, Biogen, and More (Barrons.com)
08:20AM	Amgen to invest $600M in new US center; Sanofi drug for ITP approved (BioPharma Dive)
07:00AM	Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome (Business Wire)
07:00AM	Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome (GlobeNewswire)
03:30AM	Biogen Inc. (BIIB)'s Alzheimer's Drug Leqembi Wins EU Nod, Now Approved in 48 Countries (Insider Monkey)
02:30AM	Startup Corsera Health aims to bring preventive heart medicine to the masses (BioPharma Dive)
Sep-01-25 10:31AM	Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi (Zacks)
07:15AM	FDA approves Eisai and Biogen's Leqembi Iqlik BLA for early Alzheimer's (Pharmaceutical Business Review)
Aug-29-25 05:06PM	FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment (Investor's Business Daily) +5.60%
05:00PM	FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease (PR Newswire)
Aug-25-25 07:00AM	Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress (Business Wire)
07:00AM	Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress (GlobeNewswire)
03:00AM	Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI (lecanemab) (GlobeNewswire)
Aug-21-25 05:49PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
05:05AM	Biogen Stock: Analyst Estimates & Ratings (Barchart)
Aug-19-25 07:25PM	Analyst Report: Biogen Inc. (Morningstar Research)
Aug-13-25 05:50PM	Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know (StockStory)
Aug-12-25 11:48PM	BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance (StockStory)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Grogan Jane	Head of Research	Oct 31 '25	Option Exercise	0.00	695	0	2,128	Nov 04 04:12 PM
Godbout Sean	Chief Accounting Officer	Oct 02 '25	Option Exercise	0.00	26	0	503	Oct 06 01:00 PM
Singhal Priya	Head of Development	Aug 29 '25	Option Exercise	0.00	1,669	0	7,096	Sep 02 05:56 PM
Singhal Priya	Head of Development	Sep 02 '25	Sale	133.55	517	69,045	5,772	Sep 02 05:56 PM
Singhal Priya	Officer	Sep 02 '25	Proposed Sale	133.55	517	69,045		Sep 02 12:54 PM
Izzar Rachid	Head of Global Product Strat.	Jul 08 '25	Sale	135.00	2,223	300,105	6,330	Jul 16 05:55 PM
Izzar Rachid	Officer	Jul 08 '25	Proposed Sale	135.00	2,223	300,105		Jul 08 03:26 PM
Singhal Priya	Head of Development	May 19 '25	Sale	126.25	3,806	480,508	5,427	May 20 04:05 PM
Singhal Priya	Officer	May 19 '25	Proposed Sale	126.25	3,806	480,508		May 19 11:24 AM
Keeney Adam	Head of Corporate Development	May 01 '25	Option Exercise	0.00	938	0	2,838	May 05 04:19 PM
DORSA CAROLINE	Director	May 02 '25	Buy	122.72	1,235	151,559	27,842	May 05 04:17 PM
SHERWIN STEPHEN A	Director	Mar 07 '25	Sale	150.02	8,760	1,314,142	11,318	Mar 10 04:09 PM
STEPHEN A SHERWIN	Director	Mar 07 '25	Proposed Sale	147.37	8,760	1,290,961		Mar 07 04:18 PM
Singhal Priya	Head of Development	Feb 10 '25	Option Exercise	0.00	1,212	0	9,423	Feb 12 05:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 10 '25	Option Exercise	0.00	2,272	0	14,725	Feb 12 05:47 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 10 '25	Option Exercise	0.00	3,257	0	25,712	Feb 12 05:46 PM
Kramer Robin	Chief Accounting Officer	Feb 10 '25	Option Exercise	0.00	834	0	8,257	Feb 12 05:44 PM
Gregory Ginger	EVP, Human Resources	Feb 10 '25	Option Exercise	0.00	2,159	0	18,232	Feb 12 05:43 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 10 '25	Option Exercise	0.00	2,575	0	37,072	Feb 12 05:42 PM
Izzar Rachid	Head of Global Product Strat.	Feb 10 '25	Option Exercise	0.00	1,515	0	8,998	Feb 12 05:40 PM
Izzar Rachid	Head of Global Product Strat.	Feb 07 '25	Option Exercise	0.00	3,844	0	7,860	Feb 11 09:52 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 07 '25	Option Exercise	0.00	4,551	0	23,171	Feb 10 06:59 PM
Viehbacher Christopher	President and CEO	Feb 07 '25	Option Exercise	0.00	9,008	0	16,008	Feb 10 06:55 PM
Grogan Jane	Head of Research	Feb 07 '25	Option Exercise	0.00	1,385	0	1,876	Feb 10 06:52 PM
Keeney Adam	Head of Corporate Development	Feb 07 '25	Option Exercise	0.00	1,801	0	2,463	Feb 10 06:51 PM
Kramer Robin	Chief Accounting Officer	Feb 07 '25	Option Exercise	0.00	1,491	0	7,667	Feb 10 06:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 07 '25	Option Exercise	0.00	4,042	0	13,056	Feb 10 06:47 PM
Singhal Priya	Head of Development	Feb 07 '25	Option Exercise	0.00	2,216	0	8,892	Feb 10 06:45 PM
Gregory Ginger	EVP, Human Resources	Feb 07 '25	Option Exercise	0.00	3,436	0	16,633	Feb 10 06:44 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 07 '25	Option Exercise	0.00	4,130	0	35,088	Feb 10 06:42 PM
Singhal Priya	Head of Development	Jan 31 '25	Option Exercise	0.00	1,828	0	7,254	Feb 03 06:02 PM
Singhal Priya	Head of Development	Dec 06 '24	Option Exercise	0.00	426	0	5,742	Dec 09 04:57 PM
Singhal Priya	Head of Development	Dec 09 '24	Sale	157.21	110	17,293	5,426	Dec 09 04:57 PM
Kramer Robin	Chief Accounting Officer	Dec 06 '24	Option Exercise	0.00	351	0	6,578	Dec 09 04:56 PM
Singhal Priya	Officer	Dec 09 '24	Proposed Sale	157.21	110	17,293		Dec 09 10:33 AM

Open in Screener

VSTM

Verastem Inc

Nov 07 • 04:00PM ET

8.07

+0.14 1.77 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD AMGN MRK PFE BMY REGN VRTX INCY LUMO SRPT

| Held by: VTI XBI IWM VXF FESM VTWO IWO VFMO IWN IWC

Index	RUT	P/E	-	EPS (ttm)	-4.26	Insider Own	10.25%	Shs Outstand	66.75M	Perf Week	-14.60%
Market Cap	538.88M	Forward P/E	-	EPS next Y	-1.82	Insider Trans	-1.54%	Shs Float	59.93M	Perf Month	-12.66%
Enterprise Value	490.65M	PEG	-	EPS next Q	-0.55	Inst Own	74.11%	Short Float	30.19%	Perf Quarter	4.81%
Income	-241.10M	P/S	40.28	EPS this Y	16.03%	Inst Trans	7.24%	Short Ratio	6.93	Perf Half Y	12.55%
Sales	13.38M	P/B	-	EPS next Y	40.64%	ROA	-159.02%	Short Interest	18.09M	Perf YTD	56.09%
Book/sh	-0.23	P/C	3.91	EPS next 5Y	38.19%	ROE	-2888.70%	52W High	11.24 -28.23%	Perf Year	115.78%
Cash/sh	2.06	P/FCF	-	EPS past 3/5Y	9.28% 31.36%	ROIC	-350.20%	52W Low	3.45 133.57%	Perf 3Y	71.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	154.59% -10.54%	Gross Margin	80.93%	Volatility	10.53% 8.73%	Perf 5Y	-44.88%
Dividend TTM	-	EV/Sales	36.67	EPS Y/Y TTM	-26.37%	Oper. Margin	-1197.72%	ATR (14)	0.72	Perf 10Y	-63.45%
Dividend Ex-Date	-	Quick Ratio	2.55	Sales Y/Y TTM	33.79%	Profit Margin	-1802.12%	RSI (14)	44.21	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.58	EPS Q/Q	-126.22%	SMA20	-6.74%	Beta	0.46	Target Price	16.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-10.57%	Rel Volume	0.51	Prev Close	7.93
Employees	78	LT Debt/Eq	-	Earnings	Nov 04 BMO	SMA200	15.78%	Avg Volume	2.61M	Price	8.07
IPO	Jan 27, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	-118.91% 95.30%	Trades		Volume	1,324,992	Change	1.77%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-25	Resumed	Cantor Fitzgerald	Overweight
Apr-10-25	Initiated	Jefferies	Buy	$15
Mar-24-25	Reiterated	H.C. Wainwright	Buy	$7 → $10
Dec-31-24	Reiterated	BTIG Research	Buy	$13 → $20
Sep-30-24	Initiated	Guggenheim	Buy	$13
Nov-21-23	Resumed	BTIG Research	Buy	$27
Sep-27-23	Initiated	B. Riley Securities	Buy	$21
Jun-15-23	Upgrade	Mizuho	Neutral → Buy	$24 → $36
Sep-07-22	Resumed	Alliance Global Partners	Buy	$6
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight	$6 → $5
Apr-14-22	Initiated	RBC Capital Mkts	Outperform	$5
Mar-09-22	Initiated	Truist	Buy	$6
Jul-01-21	Initiated	Alliance Global Partners	Buy	$6
May-24-21	Upgrade	BTIG Research	Neutral → Buy	$8
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy	$17
May-02-18	Initiated	Seaport Global Securities	Buy	$14
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy	$15
Sep-07-17	Reiterated	H.C. Wainwright	Buy	$6.50 → $10

Show Previous Ratings

Nov-05-25 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Nov-04-25 04:02PM	Verastem Inc (VSTM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising ... (GuruFocus.com) -20.10%
08:40AM	Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:40AM	Verastem: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
12:00PM	Loading…
Nov-03-25 12:00PM	Verastem (VSTM) Upgraded to Buy: Here's Why (Zacks)
Oct-29-25 11:57AM	Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment (Insider Monkey)
Oct-28-25 11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
Oct-23-25 04:01PM	Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors (Business Wire)
09:55AM	Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
07:30AM	Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 (Business Wire)
Oct-21-25 10:00AM	Best Momentum Stocks to Buy for Oct. 21 (Zacks)
06:39AM	New Strong Buy Stocks for Oct. 21: NEM, AS and More (Zacks)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice (Zacks) -13.02%
09:55AM	Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet (Zacks)
04:15AM	Loading…
Oct-19-25 04:15AM	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma (Business Wire)
Oct-07-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-19-25 12:00PM	Verastem (VSTM) Upgraded to Buy: Here's What You Should Know (Zacks) -5.14%
Sep-16-25 01:13PM	Top Biotech Picks for 2025: BTIG Research Highlights Potential Winners (Investing.com) -7.03%
Aug-27-25 07:00AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Aug-17-25 03:22AM	Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects (Insider Monkey)
Aug-13-25 04:29PM	Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer (Business Wire)
Aug-07-25 06:40PM	Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +19.93%
05:36PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Aug-05-25 05:55PM	Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-31-25 10:00AM	Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline (Zacks)
Jul-29-25 07:30AM	Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-24-25 07:30AM	Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer (Business Wire)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
07:42AM	Loading…
Jul-14-25 07:42AM	Verastems avutometinib combination shows 31% ORR in ovarian cancer trial (Clinical Trials Arena) +5.87%
Jul-11-25 04:12PM	Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology (Business Wire)
Jul-08-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-30-25 04:02PM	Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer (Business Wire)
Jun-24-25 04:02PM	Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors (Business Wire) -5.70%
Jun-20-25 08:41AM	Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building? (Zacks) -5.01%
Jun-02-25 09:40AM	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor (Business Wire) -19.95%
May-28-25 10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks) -10.68%
07:30AM	Verastem Oncology to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-23-25 05:15PM	Verastem announces positive Phase 1/2 safety and efficacy results in PDAC (TipRanks) +11.10%
May-22-25 05:01PM	Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma (Business Wire)
May-20-25 11:39AM	Tempus partners with Verastem for companion diagnostic development (Medical Device Network)
08:30AM	Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment (Business Wire)
May-13-25 04:50PM	Verastem: Q1 Earnings Snapshot (Associated Press Finance)
04:34PM	Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
May-09-25 11:55AM	FDA grants accelerated approval to avutometinib, defactinib combination (TipRanks)
May-08-25 02:47PM	FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer (Benzinga)
01:17PM	FDA Approves the AVMAPKI FAKZYNJA Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
May-01-25 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Apr-25-25 09:00AM	Verastem Oncology Announces $75 million Private Placement (Business Wire)
Apr-23-25 04:05PM	Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors (Business Wire) +5.34%
Apr-22-25 10:39AM	Verastem Oncology to Report Q1 Earnings: What's in the Cards? (Zacks) +13.37%
Apr-16-25 09:45AM	Top Cancer Stocks to Buy to Boost Your Portfolio's Health (Zacks)
Apr-10-25 02:35PM	Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination (Seeking Alpha) -14.39%
Apr-07-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-27-25 09:55AM	Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade (Zacks) +5.16%
Mar-25-25 04:35PM	Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 (Business Wire)
Mar-20-25 05:15PM	Verastem files to sell 1.42M shares of common stock by selling shareholders (SeekingAlpha)
04:17PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Feb-20-25 04:05PM	Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer (Business Wire)
Jan-29-25 07:30AM	Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference (Business Wire)
Jan-23-25 07:30AM	Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
Jan-15-25 07:30AM	Verastem Oncology Names Matthew E. Ros as Chief Operating Officer (Business Wire) +5.36%
Jan-14-25 07:30AM	Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China (Business Wire) -5.62%
Jan-13-25 07:30AM	Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 (Business Wire) -6.81%
Jan-08-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.79%
Dec-31-24 10:33AM	Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application (GuruFocus.com) +40.87%
Dec-30-24 04:30PM	Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
Dec-20-24 07:00AM	Applied Therapeutics Appoints John H. Johnson as Executive Chairman (GlobeNewswire) -5.63%
Dec-18-24 07:30AM	Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (Business Wire) -7.39%
Nov-26-24 07:00AM	Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-06-24 05:00PM	Verastem: Q3 Earnings Snapshot (Associated Press Finance) -6.98%
04:05PM	Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Nov-01-24 12:02PM	Verastem Oncology submits NDA for ovarian cancer treatment (Pharmaceutical Technology)
Oct-31-24 04:01PM	Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
07:30AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Oct-17-24 01:00AM	Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting (Business Wire) -20.12%
Oct-09-24 06:00AM	Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting (Business Wire)
Oct-07-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-10-24 04:05PM	Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference (Business Wire) +8.76%
07:30AM	Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting (Business Wire)
Sep-03-24 07:30AM	Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024 (Business Wire)
Aug-08-24 06:18PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Jul-29-24 04:01PM	Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer (Business Wire) -7.43%
Jul-23-24 11:20PM	Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants (Business Wire) -17.55%
04:05PM	Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants (Business Wire)
Jul-15-24 11:42AM	Verastem (VSTM) Begins Dosing in Solid Tumors Study in China (Zacks)
04:52AM	Verastem announces dosing of first patient in trial of KRAS G12D inhibitor (Clinical Trials Arena)
Jul-12-24 07:30AM	Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics (Business Wire) +12.75%
Jul-08-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-24 07:30AM	Verastem Oncology Announces Addition to Russell 3000 and Russell Microcap Indexes (Business Wire) +9.06%
Jun-19-24 07:00AM	GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation (PR Newswire)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-06-24 06:45AM	7 F-Rated Stocks to Avoid at All Costs in June (InvestorPlace)
Jun-03-24 09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
May-24-24 12:28PM	Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data (Zacks) -66.17%
11:43AM	Is the Stock Market Open on Memorial Day 2024? (InvestorPlace)

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Paterson Dan	President and CEO	Nov 03 '25	Sale	9.74	3,299	32,146	438,818	Nov 06 12:21 PM
Bunn Paul A.	Director	Oct 09 '25	Sale	9.06	8,333	75,497	8,333	Oct 14 04:31 PM
Bunn Paul A.	Board Member	Oct 09 '25	Proposed Sale	8.94	8,333	74,497		Oct 09 04:05 PM
Calkins Daniel	Chief Financial Officer	Sep 22 '25	Sale	9.08	57	518	109,863	Sep 24 04:30 PM
Calkins Daniel	Chief Financial Officer	Sep 24 '25	Sale	9.23	25	231	109,838	Sep 24 04:30 PM
Stuglik Brian M	Director	Sep 16 '25	Sale	9.99	587	5,864	101,739	Sep 18 06:16 PM
Gagnon Robert E.	Director	Sep 16 '25	Sale	9.99	281	2,807	41,961	Sep 18 06:14 PM
Paterson Dan	President and CEO	Sep 16 '25	Sale	9.99	390	3,896	442,117	Sep 18 06:11 PM
Paterson Dan	Officer	Sep 17 '25	Proposed Sale	9.76	31,790	310,429		Sep 04 12:39 PM
Paterson Dan	President and CEO	Aug 06 '25	Sale	5.81	1,332	7,739	442,507	Aug 06 08:38 PM
Paterson Dan	President and CEO	Jun 20 '25	Sale	5.13	17,808	91,355	443,839	Jun 24 04:39 PM
Calkins Daniel	Chief Financial Officer	Jun 20 '25	Sale	5.13	4,110	21,084	109,945	Jun 24 04:37 PM
Calkins Daniel	Chief Financial Officer	Jun 23 '25	Sale	4.71	25	118	109,920	Jun 24 04:37 PM
Dan Paterson	Officer	Jun 20 '25	Proposed Sale	5.13	17,808	91,334		Jun 20 05:35 PM
Paterson Dan	President and CEO	Jun 16 '25	Sale	5.65	335	1,893	461,647	Jun 20 11:22 AM
Gagnon Robert E.	Director	Jun 16 '25	Sale	5.65	284	1,605	42,242	Jun 20 11:22 AM
Stuglik Brian M	Director	Jun 16 '25	Sale	5.65	594	3,356	102,326	Jun 20 11:21 AM
Calkins Daniel	Chief Financial Officer	May 20 '25	Sale	8.13	11,143	90,593	114,055	May 20 07:54 PM
Paterson Dan	President and CEO	May 20 '25	Sale	8.13	58,677	477,044	461,982	May 20 07:52 PM
Daniel Calkins	Officer	May 20 '25	Proposed Sale	8.10	11,143	90,293		May 20 07:49 PM
Dan Paterson	Officer, Director	May 20 '25	Proposed Sale	8.13	58,677	477,044		May 20 07:48 PM
Paterson Dan	President and CEO	May 05 '25	Sale	7.30	820	5,986	345,659	May 07 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 20 '25	Sale	6.89	65	448	86,374	Mar 24 04:39 PM
Calkins Daniel	Chief Financial Officer	Mar 24 '25	Sale	7.04	26	183	86,348	Mar 24 04:39 PM
Paterson Dan	President and CEO	Mar 17 '25	Sale	6.95	244	1,696	346,479	Mar 19 04:48 PM
Gagnon Robert E.	Director	Mar 17 '25	Sale	6.95	284	1,974	34,193	Mar 19 04:47 PM
Stuglik Brian M	Director	Mar 17 '25	Sale	6.95	593	4,121	94,587	Mar 19 04:46 PM
Paterson Dan	President and CEO	Feb 04 '25	Sale	5.70	858	4,891	346,723	Feb 05 04:30 PM
Paterson Dan	President and CEO	Jan 13 '25	Sale	5.24	8,568	44,896	347,581	Jan 14 04:30 PM
Dan Paterson	Officer, Director	Jan 13 '25	Proposed Sale	5.24	8,568	44,909		Jan 13 05:03 PM
Calkins Daniel	Chief Financial Officer	Jan 06 '25	Sale	6.94	6	42	47,639	Jan 08 04:30 PM
Calkins Daniel	Chief Financial Officer	Dec 20 '24	Sale	4.34	65	282	47,396	Dec 26 04:30 PM
Calkins Daniel	Chief Financial Officer	Dec 24 '24	Sale	3.91	28	109	47,368	Dec 26 04:30 PM
Gagnon Robert E.	Director	Dec 16 '24	Sale	4.54	285	1,294	34,607	Dec 20 04:32 PM
Gagnon Robert E.	Director	Dec 19 '24	Sale	4.37	130	568	34,477	Dec 20 04:32 PM
Stuglik Brian M	Director	Dec 16 '24	Sale	4.54	595	2,701	95,514	Dec 20 04:31 PM
Stuglik Brian M	Director	Dec 19 '24	Sale	4.37	334	1,460	95,180	Dec 20 04:31 PM
Paterson Dan	President and CEO	Dec 16 '24	Sale	4.54	244	1,108	231,332	Dec 20 04:30 PM
Paterson Dan	President and CEO	Dec 19 '24	Sale	4.37	183	800	231,149	Dec 20 04:30 PM

Open in Screener

FBIO

Fortress Biotech Inc

Nov 07 • 04:00PM ET

2.61

+0.09 3.57 %

Healthcare • Biotechnology • USA • NASD

FBIO Fortress Biotech Inc daily Stock Chart

Peers: BMRN FOLD PTGX XENE MGTX TGTX QURE ANAB CRSP EDIT

| Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-1.14	Insider Own	22.64%	Shs Outstand	29.75M	Perf Week	1.95%
Market Cap	77.66M	Forward P/E	-	EPS next Y	-1.90	Insider Trans	0.00%	Shs Float	23.02M	Perf Month	-6.79%
Enterprise Value	65.95M	PEG	-	EPS next Q	-0.42	Inst Own	16.42%	Short Float	14.68%	Perf Quarter	35.94%
Income	-24.05M	P/S	1.31	EPS this Y	63.20%	Inst Trans	1.11%	Short Ratio	3.33	Perf Half Y	54.44%
Sales	59.30M	P/B	1.77	EPS next Y	-91.41%	ROA	-9.64%	Short Interest	3.38M	Perf YTD	28.89%
Book/sh	1.48	P/C	1.04	EPS next 5Y	9.86%	ROE	-47.67%	52W High	4.20 -37.86%	Perf Year	47.88%
Cash/sh	2.50	P/FCF	-	EPS past 3/5Y	39.06% 24.49%	ROIC	-22.43%	52W Low	1.33 96.98%	Perf 3Y	-79.29%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-5.71% 9.50%	Gross Margin	60.77%	Volatility	5.79% 5.49%	Perf 5Y	-92.16%
Dividend TTM	-	EV/Sales	1.11	EPS Y/Y TTM	93.42%	Oper. Margin	-182.51%	ATR (14)	0.18	Perf 10Y	-93.87%
Dividend Ex-Date	-	Quick Ratio	1.70	Sales Y/Y TTM	-28.23%	Profit Margin	-40.56%	RSI (14)	45.96	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.92	EPS Q/Q	161.49%	SMA20	0.02%	Beta	1.50	Target Price	10.50
Payout	-	Debt/Eq	1.58	Sales Q/Q	10.18%	SMA50	-14.68%	Rel Volume	0.18	Prev Close	2.52
Employees	101	LT Debt/Eq	1.44	Earnings	Aug 14 AMC	SMA200	23.72%	Avg Volume	1.02M	Price	2.61
IPO	Nov 17, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	225.00% 12.93%	Trades		Volume	186,824	Change	3.57%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Resumed	ROTH MKM	Buy	$10
Aug-04-22	Initiated	Ladenburg Thalmann	Buy	$6
Oct-02-20	Initiated	The Benchmark Company	Buy	$9
Dec-18-19	Initiated	B. Riley FBR	Buy	$9
Feb-28-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$11
Mar-22-17	Initiated	JMP Securities	Mkt Outperform
Oct-03-16	Initiated	ROTH Capital	Buy	$9

Nov-06-25 05:45PM	Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-05-25 08:30AM	Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 (GlobeNewswire)
Nov-04-25 05:15PM	Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Oct-30-25 08:15AM	Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-24-25 08:30AM	Journey Medical Corporation Reports Combined Emrosi (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference (GlobeNewswire)
08:30AM	Loading…
Oct-21-25 08:30AM	Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout (GlobeNewswire)
Oct-08-25 08:30AM	Journey Medical Corporation to Participate in October 2025 Investor Conferences (GlobeNewswire)
Oct-01-25 08:05AM	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing (GlobeNewswire) -30.72%
08:00AM	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 (GlobeNewswire)
Sep-03-25 08:30AM	Journey Medical Corporation to Participate in September 2025 Investor Conferences (GlobeNewswire)
Sep-02-25 08:30AM	Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +15.50%
Aug-18-25 08:30AM	Journey Medical Corporation to Present at the Emerging Growth Conference (GlobeNewswire) +6.13%
Aug-14-25 05:55PM	Fortress Biotech (FBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +8.16%
04:49PM	Fortress Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Loading…
Aug-12-25 04:01PM	Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-08-25 08:10AM	Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-07-25 06:25PM	Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:30AM	Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 (GlobeNewswire)
Aug-05-25 04:01PM	Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Jul-14-25 08:50AM	Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors (Zacks)
08:30AM	Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi (GlobeNewswire)
Jul-10-25 09:19AM	Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
Jun-24-25 08:30AM	Journey Medical to Join Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-20-25 08:30AM	Journey Medical Corporation Announces Emrosi Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference (GlobeNewswire)
Jun-19-25 08:50AM	Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock (Zacks)
Jun-09-25 08:30AM	Journey Medical Corporation Announces Emrosi Featured on "The Balancing Act" Airing on Lifetime TV (GlobeNewswire) +6.50%
Jun-03-25 08:50AM	Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
May-30-25 10:47AM	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics (GlobeNewswire)
May-16-25 05:50AM	New Strong Sell Stocks for May 16th (Zacks)
05:30PM	Loading…
May-15-25 05:30PM	Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.23%
04:25PM	Fortress Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:15AM	Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-14-25 05:15PM	ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-13-25 05:20PM	Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates (Zacks) +5.45%
04:15PM	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates (GlobeNewswire)
May-08-25 08:50AM	Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-07-25 04:01PM	Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 (GlobeNewswire)
08:00AM	Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference (GlobeNewswire)
Apr-01-25 04:01PM	Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer (GlobeNewswire)
Mar-31-25 05:50PM	Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-28-25 08:30AM	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates (GlobeNewswire) -6.94%
Mar-26-25 07:39PM	Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:01PM	Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-25-25 09:04AM	Fortress Biotech Inc (FBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Mar-24-25 08:30AM	Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea (GlobeNewswire)
Mar-19-25 04:01PM	Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 (GlobeNewswire)
Mar-17-25 08:55AM	Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform (GlobeNewswire)
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-12-25 08:30AM	Journey Medical Corporation to Participate in the 37th Annual ROTH Conference (GlobeNewswire)
Mar-09-25 10:06PM	Sun Pharma to Acquire Checkpoint Therapeutics (PR Newswire)
Mar-05-25 04:15PM	Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement (GlobeNewswire)
04:01PM	Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi (DFD-29) to Treat Rosacea (GlobeNewswire)
Mar-04-25 04:01PM	Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida (GlobeNewswire)
Feb-27-25 04:05PM	Mustang Bio Announces Sale of Fixed Assets and Exit of Facility (GlobeNewswire)
Feb-11-25 04:10PM	Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-10-25 08:00AM	Mustang Bio Announces Closing of $8 Million Public Offering (GlobeNewswire)
Feb-06-25 07:00AM	Mustang Bio Announces Pricing of $8 Million Public Offering (GlobeNewswire)
Jan-28-25 08:41AM	Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex (TipRanks)
07:21AM	Fortress doses first subject in Phase II CMV vaccine trial (Clinical Trials Arena)
Jan-27-25 08:30AM	Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT (GlobeNewswire)
Jan-23-25 08:30AM	Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea (GlobeNewswire)
Jan-14-25 08:00AM	Mustang Bio Announces Reverse Stock Split (GlobeNewswire)
Jan-07-25 06:59AM	FDA accepts Sentynls Menkes disease therapy NDA for priority review (Pharmaceutical Technology)
Jan-06-25 08:00AM	Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease (PR Newswire)
08:00AM	Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease (GlobeNewswire)
Dec-13-24 06:15PM	Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl) (GlobeNewswire)
Nov-14-24 05:04PM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance) -8.92%
04:10PM	Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-12-24 04:30PM	Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
04:01PM	Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Mustang Bio Receives Positive Listing Determination from Nasdaq (GlobeNewswire)
Nov-07-24 08:30AM	Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma (GlobeNewswire)
Nov-04-24 07:00AM	Journey Medical Corporation Announces U.S. FDA Approval of Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea (GlobeNewswire) -8.95%
Oct-25-24 01:02PM	Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares (GuruFocus.com) +6.94%
08:30AM	Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-24-24 02:10PM	Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds (GlobeNewswire)
Oct-09-24 08:30AM	Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit (GlobeNewswire)
Oct-03-24 08:30AM	Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-26-24 08:30AM	Fortress Biotech to Participate in October 2024 Investor Conferences (GlobeNewswire)
Sep-20-24 08:30AM	Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements (GlobeNewswire) -18.75%
Sep-16-24 07:30AM	Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 (GlobeNewswire)
Sep-09-24 08:30AM	Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference (GlobeNewswire)
Sep-04-24 08:30AM	Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.08%
08:15AM	Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
08:00AM	Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Sep-03-24 08:30AM	Avenue Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-02-24 08:50AM	Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Aug-13-24 05:15PM	Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:16PM	Fortress Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-12-24 04:01PM	Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
Aug-09-24 04:05PM	Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-06-24 04:01PM	Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024 (GlobeNewswire)
Jul-25-24 08:30AM	Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 (GlobeNewswire) +5.69%

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fortress Biotech, Inc.	10% Owner	May 29 '25	Sale	1.29	100,000	129,000	6,122,249	Jun 03 06:34 PM

BIIB

Biogen Inc

VSTM

Verastem Inc

FBIO

Fortress Biotech Inc

Upgrade your FINVIZ experience